
Blueprint Medicines BPMC.O jumps 26.5% to record high of $128.15
*Stock set for its best day on record, if gains hold
French drugmaker Sanofi SASY.PA to buy Blueprint for more than $9 billion
Sanofi paying $129/share in cash for Blueprint, a 27% premium to last close
*Brokerage Leerink Partners says the deal is "positive for the sector"
Brokerage Guggenheim says it viewed BPMC as one of its "top strategic M&A ideas of 2025"
Deal's equity value ~$9.1 billion, with potential to increase to $9.5 billion, including contingent value rights
Acquisition expected to be finalized in Q3 2025
BPMC up 16.2% this year, as of last close